Differences in glycosylation patterns of heat shock protein, gp96: Implications for prostate cancer prevention

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6466-6475

  Suriano, Robert ^a   Ghosh, Salil K ^a   Ashok, Badithe T ^a   Mittelman, Abraham ^a   Chen, Yuangen ^a   Banerjee, Asesh ^a   Tiwari, Raj K ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSUGAR; ANDROGEN; CANCER VACCINE; GLYCOPROTEIN; GLYCOPROTEIN 96; HEAT SHOCK PROTEIN; MONOSACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER PREVENTION; CONTROLLED STUDY; GLYCOSYLATION; IMMUNOGENICITY; MALE; MALIGNANT TRANSFORMATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROCESSING; RAT; TUMOR IMMUNITY; TUMOR MODEL;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; GLYCOSYLATION; HUMANS; MALE; MONOSACCHARIDES; PROSTATIC NEOPLASMS; RATS;

EID: 22244467721     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4639     Document Type: Article

References (50)

1. Srivastava PK. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002;20:395-425.
2. Sastry S, Linderoft N. Molecular mechanisms of peptide loading by tumor rejection antigen/heat shock chaperone gp96 (GRP94). J Biol Chem 1999;274:12023-35.
3. Linderoth NA, Simon MN, Hainfeld JF, Sastry S. Binding of antigenic peptide to the endoplasmic rcticulum-resident protein gp96/GRP94 heat shock chaperone occurs in higher order complexes. Essential role of some aromatic amino acid residues in the peptide-binding site. J Biol Chem 2001;276:11049-54.
4. Li Z, Srivastava PK. Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. EMBO J 1993;12:3143-51.
5. Chen YG, Ashok BT, Liu X Garikpathy VPS, Mittelman A, Tiwari RK. Induction of heat shock protein gp96 by immune cytokines. Cell Stress Chaperones 2003;8:242-8.
6. Suto R. Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995;269:1585-8.
7. Yedavelli SP, Guo L, Daou ME, Srivastava PK, Mittleman A, Tiwari RK. Preventative and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. Int J Mol Med 1999;4:243-8.
8. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000;88:232-8.
9. Caudill MM, Li Z. HSPPC-96: a personalized cancer vaccine. Expert Opin Biol Ther 2001;1:539-47.
10. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 1998;8:657-65.
11. Blachere NE, Udono H, Janetzki S, Li Z, Heike M, Srivastava PK. Heat shock protein vaccines against cancer. J Immunother 1993;14:352-6.
12. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 1994;152:5398-403.
13. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol 2000;1:151-5.
14. + cells. J Immunol 2000;165:2582-7.
15. Ploegh H, Neefjes JJ. Protein glycosylation. Curr Opin Cell Biol 1990;2:1125-30.
16. Hart GW. Glycosylation. Curr Opin Cell Biol 1992;4:1017-23.
17. Scheiffele P, Fullekrug J. Glycosylation and protein transport. Essays Biochem 2000;36:27-35.
18. Dennis JW, Granovsky M, Warren CE. Protein glycosylation in development of disease. BioEssays 1999;21:412-21.
19. Maki RG, Old LJ, Srivastava PK. Human homologue of murine tumor rejection antigen gp96: 5-prime-regulatory and coding regions and relationship to stress-induced proteins. Proc Natl Acad Sci U S A 1990;87:5658-62.
20. Feldweg AM, Srivastava PK. Molecular heterogeneity of tumor rejection antigen/heat shock protein gp96. Int J Cancer 1995;63:310-14.
21. Cala SE. GRP94 hyperglycosylation and phosphorylation in Sf21 cells. Biochim Biophys Acta 2000;1496:296-310.
22. Orntoft TF, Vestergaard EM. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 1999;20:362-71.
23. Srivastava PK, De Leo AB, Old LJ. Tumor rejection antigens of chemically induced tumors of inbred mice. Proc Natl Acad Sci U S A 1986;83:3407-11.
24. Ashok BT, Kim E, Mittelman A, Tiwari RK. Proteasome inhibitors differentially affect heat shock protein response in cancer cells. Int J Mol Med 2001;8:385-90.
25. Banerjee A, Wang R, Supernavage SL, et al. Implications of phase variation of a gene (pgtA) encoding apilin galactosyl transferase in gonococcal pathogenesis. J Exp Med 2002;196:147-62.
26. Hardy MR, Townsend RR. High-pH anion exchange chromatography of glycoprotein-derived carbohydrates. Methods Enzymol 1994;230:208-25.
27. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997;278:117-20.
28. Arsham H. Three means comparison: analysis of variance (ANOVA). Available from: http://home.ubalt. edu/ntsbarsh/Business-stat/otherapplets/ANOVA.htm.
29. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488-90.
30. Schulenberg B, Beechem JM, Patton WF. Mapping glycosylation changes related to cancer using the multiplexed proteonomics technology: a protein differential display approach. J Chromatogr B Analyt Technol Biomed Life Sci 2003;1:127-39.
31. Srivastava PK. Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune responses to cancer and in antigen presentation. Adv Cancer Res 1993;62:153-77.
32. Isaji T, Gu J, Nishiuchi R, et al. Introduction of bisecting GlcNAc into integrin α5β1 reduces ligand binding and down-regulates cell adhesion and cell migration. J Biol Chem 2004;19:19747-54.
33. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 2004;95:377-84.
34. Geng F, Shi BZ, Yuan YF, Wu XZ. The expression of core fucosylated E-cadherin in cancer cells and lung cancer patients: prognostic implications. Cell Res 2004;14:423-33.
35. WuYI, Munshi HG, Sen R, et al. Glycosylation broadens the substrate profile of membrane type matrix metalioproteinase. J Biol Chem 2004;279:8278-89.
36. Galli-Stampino L, Meinjohanns E, Frische K, et al. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res 1997;57:3214-22.
37. LaTemple DC, Henion TR, Anaraki, Galili U. Synthesis of α-galactosyl epitopes by recombinant α1,3 galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res 1996;56:3069-74.
38. LaTemple DC, Abrams JT, Zhang SY, Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for α1,3galactosyltransferase. Cancer Res 1999;59:3417-23.
39. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 2001;491:369-402.
40. Chinni SR, Gercel-Taylor C, Conner GE, Taylor DD. Cathepsin D antigenic epitopes identified by the humoral responses of ovarian cancer patients. Cancer Immunol Immunother 1998;46:48-54.
41. Irazoqui FJ, Lopez PH, Mandel U, Nores GA. Influence of terminal residue on adjacent disaccharide immunogenicity. Mol Immunol 2002;38:825-31.
42. Hakimori S. Tumor Malignancy defined by aberrant glycosylation and sphingo(glycol) lipid metabolism. Cancer Res 1996;56:5309-18.
43. Uemura S, Kabayama K, Noguchi M, Igarashi Y, Inokuchi J. Sialyation and sulfation of lactosylceramide distinctly regulate anchorage-dependent growth, apoptosis, and gene expression in 3LL Lewis lung carcinoma cells. Glycobiology 2003;13:207-16.
44. Keppler OT, Peter ME, Hinderlich S, et al. Differential sialyation of cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphocytic virus. Glycobiology 1999;9:557-69.
45. Kato T, Wang Y, Yamaguchi K, et al. Overexpression of lysosomal-type sialidase leads to suppression of metastasis associated with reversion of malignant phenotype in murine B16 melanoma cells. Int J Cancer 2001;92:797-804.
46. Dall'Olio F, Chiricolo M, Lau JT. Differential expression of the hepatic transcript of β-galactoside α 2,6 sialytransferase in human colon cancer cell lines. Int J Cancer 1999;81:243-7.
47. Recchi MA, Harduin-Lepers A, Boilly-Marer Y, Verbert A, Delannoy P. Multiplex RT-PCR method for the analysis of the expression of human sialytransferase: application to breast cancer cells. Glycoconj J 1998;15:19-27.
48. Vierbuchen MJ, Fruectnicht W, Brackrock S, Kranse KT, Zienkiewicz TJ. Quantitative lectin histochemical and immunochemical studies on the occurance of α 2,6-linked sialic acid residues in colorectal carcinomas. Relation to clinicopathological features. Cancer 1995;76:727-35.
49. Alper J. Turning sweet on cancer. Science 2003;301:159-60.
50. Moothoo ND, Naismith HJ. Concanavalin A distorts the β-GlcNAc- (1→2)-Man linkage of β-GlcNAc-(1→2)-α-Man-(1→3)- [β-GlcNAc-(1→2)-α-Man-(1→6)]-Man upon binding. Glycobiology 1998;8:173-81.